Doug is a trained lawyer with 25-years of experience working on pharmaceutical issues in Canada, including international trade, IP policy, antitrust law and pricing and reimbursement .
A reality check on MFN drug pricing: despite the rhetoric, structural and political constraints make rapid, system-wide price alignment highly unlikely. The article cuts through the noise to show why near-term impacts will be limited—and where the real policy risks and opportunities lie
Despite the recent passing of legislation of the same name by the Trudeau government, national pharmacare remains as fanciful a prospect in Canada as high-speed rail.
